Drug intelligence / Profile preview

autologous mesenchymal stem cells (Belarusian Medical Academy of Post-Graduate Education)

Development stage
Unknown
Lead developer
Belarusian Medical Academy of Postgraduate Education
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous, Intranasal
01

Overview

This is an investigational autologous cell therapy being developed by the Belarusian Medical Academy of Postgraduate Education for the treatment of Parkinson's disease. The therapy utilizes the patient's own mesenchymal stem cells (MSCs), which are harvested, processed, and then re-administered to the patient. The treatment aims to influence the pathogenesis of Parkinson's disease through multiple mechanisms, including potential neuroprotection and immunomodulation. Clinical evaluation involves two primary administration routes: a systemic intravenous method and a tandem approach combining intranasal delivery to the olfactory epithelium with intravenous infusion. The therapy is specifically being studied for its efficacy in managing both motor and non-motor symptoms in patients with rapidly progressive Parkinson's disease.

Other names
autologous mesenchymal stem cellsautologous MSCsautologous MMSC

Beyond the preview

Go deeper on autologous mesenchymal stem cells (Belarusian Medical Academy of Post-Graduate Education).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous mesenchymal stem cells (Belarusian Medical Academy of Post-Graduate Education).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call